Essayer OR - Gratuit
‘Closer India-China ties positive for both’
Business Standard
|October 04, 2025
Asian Development Bank (ADB) Chief Economist Albert Park says the fiscal position of the government seems robust despite the cuts in goods and services tax (GST) rates.
-
In an interview on the sidelines of the Kautilya Economic Conclave in New Delhi, Park tells Ruchika Chitravanshi and Asit Ranjan Mishra the 50 per cent tariffs of the United States (US) offer opportunities for India to diversify its export destinations. Edited excerpts:
‘The ADB has projected 6.5 percent growth in gross domestic product (GDP) for India in FY26 and FY27. Are there more upside or more downside risks to these projections?
There are both, but we're worried more about the downside risks because of the uncertain trade and tariff environments, and other geopolitical risks related to conflicts in Europe and West Asia. Higher oil prices may add a headwind for India. And the $0 per cent tariff by the US is high. Even though only a small share of Indian GDP depends on exports to the US, it will have an effect. It may make foreign investors have a rethink about, let’s say, a China plus one strategy; or investment in areas that would be subject to US tariffs or create risks to supply chains that end up in the US.
How serious is the tariff risk to the Indian economy?
It is the main reason for the downgrading of our forecast this year and next year, It depends on how much those tariffs will kill demand for India’s exports. There are other opportunities to diversify India’s export destinations. There are ways to adjust to the shock.
Cette histoire est tirée de l'édition October 04, 2025 de Business Standard.
Abonnez-vous à Magzter GOLD pour accéder à des milliers d'histoires premium sélectionnées et à plus de 9 000 magazines et journaux.
Déjà abonné ? Se connecter
PLUS D'HISTOIRES DE Business Standard
Business Standard
Nalco urges Odisha govt to expedite land handover process for ‘30K cr projects
Navratna central public-sector enterprise (CPSE) Nalco has requested the Odisha government to expedite the land handover process for its 30,000 crore expansion projects that will boost capacity and help it achieve the Maharatna status by 2030.
1 mins
March 10, 2026
Business Standard
Women-led startups saw 9% funding drop in 2025
Female labour participation just 42%, among lowest in G20: Axis Bank study
3 mins
March 10, 2026
Business Standard
How India can kick the West Asian oil habit
Increasing the use of alternative fuels like ethanol could be one way out
6 mins
March 10, 2026
Business Standard
India’s T20 WC win brings new stars to brand crease
\"Sachin Tendulkar carried Indian cricket on his shoulders for 21 years.
3 mins
March 10, 2026
Business Standard
UBS downgrades OMCs as oil crosses $100/bbl
The recent rally in crude prices and refining margins create a sense of déjà vu, UBS said, mirroring the 2022 oil market disruption.
1 min
March 10, 2026
Business Standard
LIC drove 18% rise in life insurers’ NBP in Feb
New business premium of life insurance companies grew 18 per cent year-on-year (Y-o-Y) to ₹35,417 crore in February, driven by robust growth at the state-owned Life Insurance Corporation of India (LIC) due to a favourable base.
1 mins
March 10, 2026
Business Standard
Why India needs Russian oil
India's oil security is becoming increasingly fragile. Over 80 per cent of its crude imports come from just two suppliers — West Asia and Russia — both now facing geopolitical stress. In this environment, resuming full purchases of Russian oil may not be a choice but a necessity. Here are eight reasons why.
3 mins
March 10, 2026
Business Standard
India, Uzbekistan launch pharma-nutra corridor
India and Uzbekistan on Monday launched a structured pharmaceutical and nutraceutical trade corridor aimed at expanding access to the Commonwealth of Independent States (CIS) and the wider Eurasian healthcare market, estimated at $7-10 billion.
1 min
March 10, 2026
Business Standard
A clear derating
Markets risk underperformance if we don’t regain our growth credentials
5 mins
March 10, 2026
Business Standard
Delhi HC allows Dr Reddy’s to make semaglutide for export
A division Bench of the Delhi High Court on Monday affirmed a single-judge Bench’s order allowing pharmaceutical company Dr Reddy’s Laboratories to manufacture the diabetes and weight-management drug semaglutide in India for export to jurisdictions where Danish drugmaker Novo Nordisk does not have patent protection.
2 mins
March 10, 2026
Listen
Translate
Change font size
